Skip to main content

Table 2 Discontinuations of treatment in the course of the study

From: Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study

 

Concomitant AIT

n (%)

No concomitant AIT

n (%)

All patients treated

n (%)

Patients

160

21

181

Discontinuation due to

 AEs

14 (8.8)

1 (4.8)

15 (8.3)

 Patient moved

1 (0.6)

1 (4.8)

2 (1.1)

 Withdrawal of consent

1 (0.6)

1 (0.6)

 Tablet application too complicated

1 (0.6)

1 (0.6)

 Not returned after 1st administration of SQ® grass SLIT-tablet

2 (1.3)

1 (4.8)

3 (1.7)

Patients continuing treatment

141 (88.1)

18 (85.7)

159 (87.8)